CARA Stock UPDATES Cara Therapeutics Inc. (CARA) 10.01 09/16/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 16, 2014 at 7:39 PM

Cara Therapeutics Inc. (CARA) 10.01 $CARA

Cara Therapeutics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced financial results for the second quarter ended June 30, 2014.

Cara Therapeutics Initiates Proof-of-Concept Phase II Trial of I.V. CR845 in Uremic Pruritus
GlobeNewswire - Wed Aug 06, 7:00AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced the dosing of the first dialysis patients in a Phase II trial of an intravenous formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of uremic pruritus. The company expects to report top-line data from this trial in the first half of 2015.

Cara Therapeutics to Announce Second Quarter 2014 Financial Results on August 7, 2014
GlobeNewswire - Thu Jul 31, 3:01PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Thursday, August 7, 2014, at 4:30 p.m. ET to report second quarter 2014 financial results and provide a corporate update.

Cara Therapeutics Initiates Human Abuse Liability Trial of CR845
GlobeNewswire - Thu Jul 31, 7:09AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a human abuse liability (HAL) trial of an intravenous formulation of its peripherally-selective kappa opioid agonist, CR845. The company expects to report top-line data from this trial in the fourth quarter of 2014.

Cara Therapeutics receives milestone payment for completing its Phase 1 single and multiple ascending dose trial of IV CR845 in Japanese population
M2 - Thu Jul 17, 8:11AM CDT
Biopharmaceutical company Cara Therapeutics (NasdaqGM:CARA) revealed on Wednesday the receipt of a USD500,000 milestone payment from Maruishi Pharmaceutical Company for the completion of its Phase 1 clinical trial of the IV formulation of CR845 in Japan.

Cara Therapeutics Earns Milestone Payment From Maruishi Pharmaceutical for Completion of Phase 1 Clinical Trial of I.V. CR845 in Japan
GlobeNewswire - Wed Jul 16, 7:23AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that it has earned a $500,000 milestone payment from Maruishi Pharmaceutical Company, Ltd., for the completion of Maruishi's Phase 1 clinical trial of the I.V. formulation of Cara's novel kappa opioid agonist, CR845, in Japan.

3 Stocks Rising on Unusual Volume
at The Street - Tue Jul 01, 7:13AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Cara Therapeutics Announces Appointment of Robert Medve, M.D., as Chief Medical Officer
GlobeNewswire - Tue Jun 24, 7:07AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that Dr. Robert Medve has been named Chief Medical Officer, effective immediately. Dr. Medve will oversee the clinical development of Cara's lead compound, CR845, as well as its pipeline of other novel pain therapies.

Strength Seen in Cara Therapeutics Inc. (CARA) as Stock Rallies 19.60% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:44AM CDT
Cara Therapeutics Inc. (CARA) was a big mover last session, as the company saw its shares surge over 19% on the day.

Why Cara Therapeutics Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 20, 12:38PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Cara Therapeutics , a clinical-stage...

Enteris BioPharma Oral Peptide Delivery Technology Enables Key Clinical Milestone for Acute and Chronic Pain Drug
PR Newswire - Fri Jun 20, 7:10AM CDT
Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced that its development partner, Cara Therapeutics (Nasdaq: CARA) has dosed the first subjects in a further Phase 1a/1b clinical trial of a tablet formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain.

Cara Therapeutics Initiates Phase Ia/Ib Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain
GlobeNewswire - Wed Jun 18, 7:08AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the dosing of the first subjects in a Phase Ia/Ib clinical trial of an oral tablet formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain. The company expects to report top-line pharmacokinetic, safety and biomarker data in the fourth quarter of 2014.

Cara Therapeutics Inc. (CARA) Worth Watching: Stock Surges 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:57AM CDT
Cara Therapeutics Inc. was a big mover last session, as the company saw its shares rise nearly 13% on the day.

Cara Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 27, 3:12PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and full year ended December 31, 2013.

Cara Therapeutics to Announce Fourth Quarter and Full Year 2013 Financial Results on March 27, 2014
GlobeNewswire - Thu Mar 20, 3:01PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Thursday, March 27, 2014, at 4:30 p.m. ET to report fourth quarter and full year 2013 financial results and provide a corporate update.

'Mad Money' Lightning Round: No Fan of Lionsgate
at The Street - Thu Mar 13, 5:00AM CDT
Cramer is cautious on Cara Therapeutics but thinks DaVita is a terrific health care play.

Jim Cramer's 'Mad Money' Recap: Lost in the Rotation
at The Street - Wed Mar 12, 7:07PM CDT
The market's gyrations may seem maddening to those with longer-term views so those investors need to stay diversified, Cramer says.

New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:39AM CST
Cara Therapeutics Inc. was a big mover last session, as its shares surged over 12% on the day.

Cara Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Wed Feb 05, 3:01PM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the closing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $11.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock at the same price to cover over-allotments.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Employment Law Suit Hits ABC: Alleged Wage Violations

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...